ReviewEssays in biochemistry2024
Specificity and diversity of Klebsiella pneumoniae phage-encoded capsule depolymerases.
Review in Essays in biochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2026Pooled it
- Article
- Mapping structural constraints and adaptive potential in a capsule-degrading phage tailspike protein.Science advances · 2026Article
- Article
- Effect of Structural Trimming on the Therapeutic Efficacy of K2 Capsule Depolymerase'sAntibiotics (Basel, Switzerland) · 2026Article
- Unraveling a new Klebsiella phage KP47 against Klebsiella spp.BMC microbiology · 2026Article
- Phage-Encoded Depolymerase DepKP144 with Therapeutic Potential Against Both K1- and K2-TypeInternational journal of molecular sciences · 2026Article
- DepoCatalog: mapping diversity of 129 recombinantly produced Klebsiella phage depolymerases.Nature communications · 2026Article
- Cross-genus phage design through branching domain and conserved peptide interactions.Journal of biological engineering · 2026Article
- Capsular specificity in temperate phages of Klebsiella pneumoniae is driven by diverse receptor-binding enzymes.PLoS biology · 2026Article
- Programmable Klebsiella pneumoniae Phage Tropism Enabled by Scalable Receptor-Binding Protein Mining and Modular Assembly.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Phage-antibiotic synergy restores β-lactam efficacy in MDR Klebsiella quasipneumoniae biofilms and suppresses resistance.Journal of biomedical science · 2026Article
- Hospital-adapted inhaled phage therapy for ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae: a comparative pilot study.Critical care (London, England) · 2026Article
- Characterization and Therapeutic Potential of a Novel Lytic Bacteriophage vB_Kp_H122 Targeting Multidrug-Resistant Hypervirulent Klebsiella pneumoniae of K57 Capsular Type.Transboundary and emerging diseases · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Characterization of NovelViruses · 2025Article
- The N-Terminal Domain of Tailspike Depolymerases Affects the Replication Efficiency of SyntheticInternational journal of molecular sciences · 2025Article
- Mapping Structural Constraints and Adaptive Potential in a Capsule-Degrading Phage Tailspike Protein.bioRxiv : the preprint server for biology · 2025Article
- Isolation and characterization of a novel phage targeting Klebsiella pneumoniae K2 capsular type.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Characterization and Therapeutic Potential of Three Depolymerases Against K54 Capsular-TypeMicroorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Klebsiella pneumoniae is an opportunistic pathogen with significant clinical relevance. K. pneumoniae-targeting bacteriophages encode specific polysaccharide depolymerases with the ability to selectively degrade the highly varied protective capsules, allowing for access to the bacterial cell wall. Bacteriophage depolymerases have been proposed as novel antimicrobials to combat the rise of multidrug-resistant K. pneumoniae strains. These enzymes display extraordinary diversity, and are key determinants of phage host range, however with limited data available our current knowledge of their mechanisms and ability to predict their efficacy is limited. Insight into the resolved structures of Klebsiella-specific capsule depolymerases reveals varied catalytic mechanisms, with the intra-chain cleavage mechanism providing opportunities for recombinant protein engineering. A detailed comparison of the 58 characterised depolymerases hints at structural and mechanistic patterns, such as the conservation of key domains for substrate recognition and phage tethering, as well as diversity within groups of depolymerases that target the same substrate. Another way to understand depolymerase specificity is by analyzing the targeted capsule structures, as these may share similarities recognizable by bacteriophage depolymerases, leading to broader substrate specificities. Although we have only begun to explore the complexity of Klebsiella capsule depolymerases, further research is essential to thoroughly characterise these enzymes. This will be crucial for understanding their mechanisms, predicting their efficacy, and engineering optimized enzymes for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.